Nintedanib (Ofev®)

Status
To Patients
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Oral Drug
Funder Type
Industry

Drug Details

Nintedanib (Ofev®): Nintedanib is an anti-fibrotic drug that is approved to treat idiopathic pulmonary fibrosis in the United States, Europe, and Australia. In clinical trials, nintedanib has been shown to slow the decline in lung function in mild-to-moderate idiopathic pulmonary fibrosis. It is taken by mouth twice a day.

More Information

OFEV.com

PFF Nintedanib Fact Sheet

Find a Clinical Trial

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >